Catherine Beauchemin

BSc University of Ottawa, PhD University of Alberta
Associate Professor

Profile picture - Catherine Beauchemin
KHS 331
350 Victoria St. Toronto, ON M5B 2K3
t. 416-979-5000 x2508
f. 416-979-5343
Research Website


Virophysics: use of physical models to resolve the temporal and spatial dynamics of viral infections. Specifically, the development of realistic mathematical and computer models to capture and expalin the kinetics of virus infection spread within a cell culture (in vitro) or a host (in vivo). Apply physical models to accurately quantify the mode of action and efficacy of antiviral drugs and the phenotypic effect of virus mutations which confer drug resistance. Virus of primary interest: influenza, hepatitis C, dengue, and the respiratory syncitial virus.

Research Projects

The phymbie research group has many ongoing projects. Visit the phymbie website for more details about projects and opened positions. You might also want to watch this short video...

Selected Publications

  • Dobrovolny, HM and CAA Beauchemin. Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response, and antiviral mechanisms. PLoS ONE. (PONE-D-17-07604R2) Accepted June 19, 2017.

  • CAA Beauchemin, T. Miura, and S. Iwami. Duration of SHIV production by infected cells is not exponentially distributed: Implications for estimates of infection parameters and antiviral efficacy. Sci. Rep., 7:42765, 2017. doi:10.1038/srep42765

  • Palmer, J, HM Dobrovolny, and CAA Beauchemin. The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients. Sci. Rep., 7:40210, 2017. doi:10.1038/srep40210

  • Liao, LE, S Iwami, and CAA Beauchemin. (In)validating experimentally derived knowledge about influenza A defective interfering particles. J. R. Soc. Interface, 13(124):20160412, 2016. doi:10.1098/rsif.2016.0412

  • Lipsitch, M, W Barclay, R Raman, CJ Russell, JA Belser, S Cobey, PM Kasson, JO Lloyd-Smith, S Maurer-Stroh, S Riley, CAA Beauchemin, T Bedford, TC Friedrich, A Handel, S Herfst, PR Murcia, B Roche, CO Wilke, and CA Russell. Viral factors in influenza pandemic risk assessment. eLife, 5:e18491, 2016. doi:10.7554/eLife.18491

  • Simon, PF, MA de La Vega, E Paradis, E Mendoza, KM Coombs, D Kobasa, and CAA Beauchemin. Avian influenza viruses that cause highly virulent infections in humans exhibit distinct replicative properties in contrast to human H1N1 viruses. Sci. Rep., 6:24154, 2016. doi:10.1038/srep24154

  • Kamal, MA, R Gieschke, A Lemenuel-Diot, CAA Beauchemin, PF Smith, and CR Rayner. A drug-disease model decribing the effect of oseltamivir neuraminidase inhibition on influenza virus progression. Antimicrob. Agents Chemother., 59(9):5388-5395, 2015. doi:10.1128/AAC.00069-15

  • Kakizoe, Y, S Morita, S Nakaoka, Y Takeuchi, K Sato, T Miura, CAA Beauchemin, and S Iwami. A conservation law for virus infection in vitro. J. Theor. Biol., 376:39-47, 2015. doi:10.1016/j.jtbi.2015.03.034

  • Kakizoe, Y, S Nakaoka, CAA Beauchemin, S Morita, H Mori, T Igarashi, K Aihara, T Miura, and S Iwami. A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic simian human immunodeficiency virus strain. Sci. Rep., 5:10371, 2015. doi:10.1038/srep10371

  • Paradis, EG, LT Pinilla, BP Holder, Y Abed, G Boivin, and CAA Beauchemin. Impact of the H275Y and I223V mutations in the neuraminidase of the 2009 pandemic influenza virus in vitro and evaluating experimental reproducibility.. PLoS ONE, 10(5):e0126115, 2015. doi:10.1371/journal.pone.0126115


  • NSERC Discovery Grant (2008-2013, 2013-2018)
  • CIHR Operating Grant (PI: Guy Boivin)
  • Research contracts - Pharmaceutical/Virological
  • Ontario Early Researcher Award (2014-2019)




Group Members

See the phymbie research team page.

Research Collaborators

See the phymbie research team page.

Thesis Links

See the theses of the phymbie group members next to their profile on the phymbie research team page.